Reshma Kewalramani, CEO & President at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 6,596 shares at $338.69 ($2.2M) on 2023-04-27, disclosed to the SEC on 2023-05-01.
Scheduled sale ($2.2M) by CEO & President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $338.69 | 1,611 | $546K | 24.4% |
| 2 | $338.69 | 1,611 | $546K | 24.4% |
| 3 | $339.43 | 1,668 | $566K | 25.3% |
| 4 | $339.43 | 1,668 | $566K | 25.3% |
| 5 | $340.19 | 38 | $13K | 0.6% |
| Total | $339.07 avg | 6,596 |
| $2.2M |
| 100% |
| Filing → |
| VRTX | SELL | 2024-11-12 | $7.8M | — | Filing → |
| VRTX | SELL | 2024-08-01 | $7.7M | — | Filing → |
| VRTX | SELL | 2024-07-24 | $7.6M | — | Filing → |